The role of dipeptidyl peptidase - 4 inhibitors in diabetic kidney disease

Frontiers in Immunology

Volumn 6, Issue AUG, 2015, Pages

  Panchapakesan, Usha ^a   Pollock, Carol ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Diabetic kidney disease; Dipeptidyl peptidase 4; Fibrosis; Inflammation; Renoprotection

Indexed keywords

ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIMEPIRIDE; LATENCY ASSOCIATED PEPTIDE; LINAGLIPTIN; TRANSFORMING GROWTH FACTOR BETA;

CARDIOVASCULAR DISEASE; DIABETES CONTROL; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEIOTROPY; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; RISK REDUCTION; SHORT SURVEY; WEIGHT GAIN;

EID: 84941272190     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00443     Document Type: Short Survey

References (45)

1. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology (2007) 132(6):2131-57. doi:10.1053/j.gastro.2007.03.054.
2. Ansorge S, NordhoffK, Bank U, Heimburg A, Julius H, Breyer D, et al. Novel aspects of cellular action of dipeptidyl peptidase IV/CD26. Biol Chem (2011) 392(3):153-68. doi:10.1515/BC.2011.008.
3. Oravecz T, Pall M, Roderiquez G, Gorrell MD, Ditto M, Nguyen NY, et al. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage. J Exp Med (1997) 186(11):1865-72. doi:10.1084/jem.186.11.1865.
4. Proost P, De Meester I, Schols D, Struyf S, Lambeir AM, Wuyts A, et al. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J Biol Chem (1998) 273(13):7222-7. doi:10.1074/jbc.273.13.7222.
5. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC Jr. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol (2007) 292(2):R897-901. doi:10.1152/ajpregu.00569.2006.
6. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpe S, De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem (2006) 52(1):82-7. doi:10.1373/clinchem.2005.057638.
7. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept (1999) 85(1):9-24. doi:10.1016/S0167-0115(99)00089-0.
8. Marchetti C, Di Carlo A, Facchiano F, Senatore C, De Cristofaro R, Luzi A, et al. High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. Diabetologia (2012) 55(1):236-44. doi:10.1007/s00125-011-2213-6.
9. Heymann E, Mentlein R. Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. FEBS Lett (1978) 91(2):360-4. doi:10.1016/0014-5793(78)81210-1.
10. Sharoyan S, Antonyan A, Mardanyan S, Harutyunyan H, Movsisyan N, Hovnanyan N, et al. Interaction of dipeptydil peptidase IV with amyloid peptides. Neurochem Int (2013) 62(8):1048-54. doi:10.1016/j.neuint.2013.03.017.
11. Broxmeyer HE, Hoggatt J, O'Leary HA, Mantel C, Chitteti BR, Cooper S, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med (2012) 18(12):1786-96. doi:10.1038/nm.2991.
12. O'Leary H, Ou X, Broxmeyer HE. The role of dipeptidyl peptidase 4 in hematopoiesis and transplantation. Curr Opin Hematol (2013) 20(4):314-9. doi:10.1097/MOH.0b013e32836125ac.
13. Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol (2003) 82(2):53-73. doi:10.1078/0171-9335-00302.
14. Aertgeerts K, Ye S, Shi L, Prasad SG, Witmer D, Chi E, et al. N-linked glycosylation of dipeptidyl peptidase IV (CD26): effects on enzyme activity, homodimer formation, and adenosine deaminase binding. Protein Sci (2004) 13(1):145-54. doi:10.1110/ps.03352504.
15. Ohnuma K, Uchiyama M, Yamochi T, Nishibashi K, Hosono O, Takahashi N, et al. Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1. J Biol Chem (2007) 282(13):10117-31. doi:10.1074/jbc. M609157200.
16. Ohnuma K, Takahashi N, Yamochi T, Hosono O, Dang NH, Morimoto C. Role of CD26/dipeptidyl peptidase IV in human T cell activation and function. Front Biosci (2008) 13:2299-310. doi:10.2741/2844.
17. Ikushima H, Munakata Y, Ishii T, Iwata S, Terashima M, Tanaka H, et al. Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor II receptor contributes to T cell activation. Proc Natl Acad Sci U S A (2000) 97(15):8439-44. doi:10.1073/pnas.97.15.8439.
18. Ikushima H, Munakata Y, Iwata S, Ohnuma K, Kobayashi S, Dang NH, et al. Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cell Immunol (2002) 215(1):106-10. doi:10.1016/S0008-8749(02)00010-2.
19. Khurana S, Margamuljana L, Joseph C, Schouteden S, Buckley SM, Verfaillie CM. Glypican-3-mediated inhibition of CD26 by TFPI: a novel mechanism in hematopoietic stem cell homing and maintenance. Blood (2013) 121(14):2587-95. doi:10.1182/blood-2012-09-456715.
20. Raj VS, Mou H, Smits SL, Dekkers DH, Muller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature (2013) 495(7440):251-4. doi:10.1038/nature12005.
21. Tinoco AD, Tagore DM, Saghatelian A. Expanding the dipeptidyl peptidase 4-regulated peptidome via an optimized peptidomics platform. J Am Chem Soc (2010) 132(11):3819-30. doi:10.1021/ja909524e.
22. Lone AM, Nolte WM, Tinoco AD, Saghatelian A. Peptidomics of the prolyl peptidases. AAPS J (2010) 12(4):483-91. doi:10.1208/s12248-010-9208-y.
23. Tiruppathi C, Miyamoto Y, Ganapathy V, Roesel RA, Whitford GM, Leibach FH. Hydrolysis and transport of proline-containing peptides in renal brush-border membrane vesicles from dipeptidyl peptidase IV-positive and dipeptidyl peptidase IV-negative rat strains. J Biol Chem (1990) 265(3):1476-83.
24. Panchapakesan U, Gross S, Gangadharan Komala M, Pegg K, Pollock C. DPP4 inhibition in human kidney proximal tubular cells-renoprotection in diabetic nephropathy? J Diabetes Metab (2013) S9:007. doi:10.1371/journal.pone.0054442.
25. Miyazono K, Heldin CH. Latent forms of TGF-beta: molecular structure and mechanisms of activation. Ciba Found Symp (1991) 157:81-9.
26. Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, et al. Dipeptidyl peptidase (DPP) IV inhibitor attenuates kidney injury in streptozotocin induced diabetic rats. J Pharmacol Exp Ther (2011) 340(2):248-55. doi:10.1124/jpet.111.186866.
27. Mega C, Teixeira de Lemos E, Vala H, Fernandes R, Oliveira J, Mascarenhas-Melo F, et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (zucker diabetic fatty rat). Exp Diabetes Res (2011) 2011:162092. doi:10.1155/2011/162092.
28. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int (1995) 47(6):1703-20. doi:10.1038/ki.1995.236.
29. Min HS, Kim JE, Lee MH, Song HK, Kang YS, Lee MJ, et al. Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction. Lab Invest (2014) 94(6):598-607. doi:10.1038/labinvest.2014.50.
30. Matsui T, Nakashima S, Nishino Y, Ojima A, Nakamura N, Arima K, et al. Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis. Lab Invest (2015) 95(5):525-33. doi:10.1038/labinvest.2015.35.
31. Nakashima S, Matsui T, Takeuchi M, Yamagishi SI. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm Metab Res (2014) 46(10):717-21. doi:10.1055/s-0034-1371892.
32. Nistala R, Habibi J, Aroor A, Sowers JR, Hayden MR, Meuth A, et al. DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese rat. Obesity (Silver Spring) (2014) 22(10):2172-9. doi:10.1002/oby.20833.
33. Nistala R, Habibi J, Lastra G, Manrique C, Aroor AR, Hayden MR, et al. Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology (2014) 155(6):2266-76. doi:10.1210/en.2013-1920.
34. Shi S, Srivastava SP, Kanasaki M, He J, Kitada M, Nagai T, et al. Interactions of DPP-4 and integrin beta1 influences endothelial-to-mesenchymal transition. N Engl J Med (2015) 373(3):232-42. doi:10.1038/ki.2015.103.
35. Salheen SM, Panchapakesan U, Pollock CA, Woodman OL. The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose. Pharmacol Res (2015) 94:26-33. doi:10.1016/j.phrs.2015.02.003.
36. Higashijima Y, Tanaka T, Yamaguchi J, Tanaka S, Nangaku M. Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury. Am J Physiol Renal Physiol (2015) 308(8):F878-87. doi:10.1152/ajprenal.00590.2014.
37. Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, et al. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes. Biochem Biophys Res Commun (2014) 443(3):828-33. doi:10.1016/j.bbrc.2013.12.049.
38. Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S, et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun (2013) 434(2):191-6. doi:10.1016/j.bbrc.2013.03.010.
39. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs (2011) 71(11):1441-67. doi:10.2165/11591400-000000000-00000.
40. Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs-insights from the rosiglitazone experience. N Engl J Med (2013) 369(14):1285-7. doi:10.1056/NEJMp1309610.
41. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 369(14):1317-26. doi:10.1056/NEJMoa1307684.
42. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 369(14):1327-35. doi:10.1056/NEJMoa1305889.
43. Mullard A. DPP4 inhibitors d0dge cardiovascular bullet. Nat Rev Drug Discov (2015) 14(May):301. doi:10.1038/nrd4635.
44. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med (2015). doi:10.1056/NEJMoa1501352.
45. Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care (2011) 34(1):90-5. doi:10.2337/dc10-1393.